Earlier this week, the U.S. Supreme Court issued its decision in Federal Trade Commission v. Actavis. As the Court's first pronouncement in this area, the decision promises to have an immense impact on how pharmaceutical companies prosecute and settle patent infringement lawsuits against one another.

In particular, the opinion holds that district courts should apply the "rule of reason" standard in assessing antitrust liability for so-called reverse payment patent settlements, i.e., settlements in which the generic manufacturer receives cash from the brand name manufacturer. Please join us for a panel discussion among practitioners and economists of the Court's ruling and its implications.  


12:00 PM - 1:00 PM ET | Webinar


Leslie E. John, Ballard Spahr
Edward D. Rogers, Ballard Spahr
Jason A. Leckerman, Ballard Spahr
Pierre Y. Cremieux, Ph.D., Analysis Group
Sally D. Woodhouse, Ph.D., Cornerstone Research

There is no cost to attend. This program is not eligible for continuing education credits.

Please register at least two days before the webinar. Login details will be sent to all approved registrants. For more information, contact Lisa Prickril at 215.864.8252 or prickrill@ballardspahr.com.

Program Contact

Lisa Prickril